Alps Advisors Inc. Sells 8,377 Shares of Medtronic PLC $MDT

Alps Advisors Inc. trimmed its holdings in Medtronic PLC (NYSE:MDT) by 30.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,915 shares of the medical technology company’s stock after selling 8,377 shares during the quarter. Alps Advisors Inc.’s holdings in Medtronic were worth $1,801,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Riverbend Wealth Management LLC raised its position in shares of Medtronic by 3.2% during the third quarter. Riverbend Wealth Management LLC now owns 3,487 shares of the medical technology company’s stock valued at $332,000 after buying an additional 107 shares during the last quarter. Wynn Capital LLC raised its holdings in Medtronic by 2.4% in the 3rd quarter. Wynn Capital LLC now owns 4,639 shares of the medical technology company’s stock valued at $442,000 after acquiring an additional 110 shares in the last quarter. Meridian Investment Counsel Inc. raised its holdings in Medtronic by 0.4% in the 3rd quarter. Meridian Investment Counsel Inc. now owns 28,268 shares of the medical technology company’s stock valued at $2,692,000 after acquiring an additional 110 shares in the last quarter. Saxony Capital Management LLC increased its position in shares of Medtronic by 3.8% during the third quarter. Saxony Capital Management LLC now owns 3,046 shares of the medical technology company’s stock valued at $290,000 after purchasing an additional 112 shares during the period. Finally, Cape Investment Advisory Inc. increased its position in shares of Medtronic by 3.2% during the second quarter. Cape Investment Advisory Inc. now owns 3,605 shares of the medical technology company’s stock valued at $314,000 after purchasing an additional 113 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on MDT shares. The Goldman Sachs Group set a $111.00 price target on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. UBS Group restated a “neutral” rating and set a $104.00 price target on shares of Medtronic in a research note on Wednesday, February 4th. CICC Research initiated coverage on Medtronic in a report on Friday, January 30th. They set an “outperform” rating on the stock. Finally, Daiwa Securities Group increased their target price on Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a report on Tuesday, November 25th. Sixteen analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $111.21.

Medtronic Price Performance

Medtronic stock opened at $101.37 on Wednesday. The business’s fifty day moving average is $99.36 and its two-hundred day moving average is $96.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.80 and a current ratio of 2.42. The firm has a market cap of $129.96 billion, a P/E ratio of 27.32, a P/E/G ratio of 2.68 and a beta of 0.71. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the previous year, the business posted $1.26 earnings per share. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities research analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were given a $0.71 dividend. This represents a $2.84 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is 76.55%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire CathWorks for $585 million — expands its cath-lab/FFR imaging capabilities and strengthens the cardiovascular franchise, a strategic tuck-in that could accelerate revenue and cross‑sell opportunities. Medtronic to Buy CathWorks for $585M
• Positive Sentiment: Needham upgraded MDT to a “buy” and set a $121 price target (~19% upside from current levels) — the upgrade can attract buying interest and supports near-term sentiment. Needham upgrades Medtronic (MDT)
• Positive Sentiment: Analysts and trade press note new product momentum and related rating boosts — fresh product launches/approvals bolster growth narrative and margin leverage over time. Medtronic stock gets a ratings boost on new products
• Positive Sentiment: Outlook drivers: Zacks highlights strength in Medtronic’s cardiovascular unit as a likely lift to Q3 revenue (projected ~7.3% y/y), which could offset softer EPS. Strength in Cardiovascular Unit Likely to Lift MDT’s Q3 Performance
• Neutral Sentiment: MDT is expected to report earnings this week — the print and any revised FY guidance remain the primary short-term catalyst. Medtronic (MDT) Expected to Announce Earnings on Tuesday
• Neutral Sentiment: Analyst/market narratives are shifting as Medtronic’s strategic moves and pipeline progress get priced in — read for context on repositioning and valuation. How Recent Moves Are Quietly Rewriting The Story For Medtronic (MDT)
• Neutral Sentiment: Market note: the stock recently dipped while broader markets gained — a short-term trading signal but not a fundamental verdict. Medtronic (MDT) Stock Dips While Market Gains: Key Facts
• Negative Sentiment: An antitrust verdict awarded roughly $381.7M in damages against Medtronic — this legal cost and any follow‑on litigation/settlement risk can pressure near‑term earnings and valuation multiples. A Look At Medtronic (MDT) Valuation After Major Antitrust Verdict And US$381.7m Damages Award

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).